Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29578425 | 1.00 | PKM (0.72) | PKMCYP1A2CCR1FERMT2CCNC | |
| Hydrochloric Acid SCHEMBL7837900 | 0.99 | PKM (0.70) | PKMCYP1A2CCR1FERMT2CCNC | |
| Hydrochloric Acid SCHEMBL7836012 | 0.93 | PKM (0.61) | PKMCYP1A2CCR1FERMT2KDM4E | |
| SCHEMBL4281724 | 0.92 | PKM (0.60) | PKMCYP1A2CCR1FERMT2KDM4E | |
| Hydrochloric Acid SCHEMBL7838222 | 0.92 | PKM (0.59) | PKMCYP1A2CCR1FERMT2KDM4E | |
| SCHEMBL7837912 | 0.91 | PKM (0.58) | PKMCYP1A2CCR1FERMT2KDM4E | |
| Hydrochloric Acid SCHEMBL7825267 | 0.90 | PKM (0.58) | PKMCYP1A2CCR1FERMT2 | |
| Hydrochloric Acid SCHEMBL7840186 | 0.89 | CYP1A2 (0.55) | PKMCYP1A2CCR1FERMT2KDM4E | |
| Hydrochloric Acid SCHEMBL7840125 | 0.88 | PKM (0.56) | PKMCYP1A2CCR1FERMT2KDM4E | |
| Hydrochloric Acid SCHEMBL7839361 | 0.87 | PKM (0.55) | PKMCYP1A2CCR1FERMT2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | claimed |
| EP-0876346-B1 | ANTIMALARIAL QUINOLIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-07-25 | — | — | EP | claimed |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | disclosed |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-08-20 | — | — | US | disclosed |
| US-9073985-B2 | Methods and products for treating proliferative diseases | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-07-07 | — | — | US | disclosed |
| US-8440695-B2 | Use of chloroquine to treat metabolic syndrome | ST JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110318335-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2011-12-29 | — | — | US | disclosed |
| US-20090099134-A1 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2009-04-16 | — | — | US | disclosed |
| US-20080319010-A1 | Use of Chloroquine to Treat Metabolic Syndrome | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2008-12-25 | — | — | US | disclosed |
| US-20060241139-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2006-10-26 | — | — | US | disclosed |
| US-7084157-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-08-01 | — | — | US | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| EP-0876346-B1 | ANTIMALARIAL QUINOLIN DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | PKM 2712/4885CYP1A2 2466/4885CCR1 2075/4885 |
| US-20090099134-A1 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | BRCA1, ERCC4, POLN | PKM 3551/4885CYP1A2 2838/4885CCR1 4009/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | PKM 3037/4885CYP1A2 2253/4885CCR1 2064/4885 |
| US-20110318335-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, KDR | PKM 167/4885CYP1A2 2114/4885CCR1 2315/4885 |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | AQP4, IL5, CCL11 | PKM 1586/4885CYP1A2 876/4885CCR1 413/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | PKM 3551/4885CYP1A2 2838/4885CCR1 4009/4885 |
| US-20080319010-A1 | Use of Chloroquine to Treat Metabolic Syndrome | NPC1L1, ECHS1, PCSK9 | PKM 1607/4885CYP1A2 582/4885CCR1 2237/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | PKM 4099/4885CYP1A2 573/4885CCR1 3970/4885 |
| US-20150231237-A1 | METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES | BECN1, G6PD, VHL | PKM 163/4885CYP1A2 2391/4885CCR1 2283/4885 |
| US-20060241139-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | PKM 3551/4885CYP1A2 2838/4885CCR1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.